When Insook Jang, Ph.D., and her colleagues at Sanford Burnham Prebys peered into insulin-producing beta cells, they found something both elegant and fragile: a molecular system working like a well-practiced tennis doubles team, where every partner matters for victory. Their new research, published in the Proceedings of the National Academy of Sciences, reveals how protecting this partnership could shield insulin-making cells from the damage that drives diabetes.
The research team, led by Randal J. Kaufman, Ph.D., a professor in the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys, was investigating a fundamental cellular problem. As prediabetes progresses into diabetes, proteins in beta cells begin to misfold—imagine origami paper crumpling instead of folding into precise shapes. These deformed proteins accumulate like discarded wads in a student's recycling bin, stressing the very cells responsible for producing insulin. Understanding which proteins guide this folding process became the team's urgent focus.
Scientists had already identified that misfolding of proinsulin, a precursor molecule essential for insulin production, occurs during diabetes. But what remained unclear was which partner proteins helped prevent this misfolding and how they worked together. The Kaufman lab knew that a chaperon protein called binding immunoglobulin protein, or BiP, coordinated this system, but the role of its cochaperone partners remained mysterious.
To solve this puzzle, the research team genetically modified mice so that BiP in their beta cells carried a 3xFLAG tag—three sets of an eight-amino-acid sequence that acted like a molecular beacon, allowing them to track and isolate BiP during experiments. What they discovered highlighted one cochaperone in particular: p58IPK.
When the scientists removed p58IPK from two different cell lines, misfolded proinsulin accumulated dramatically. Mice genetically altered to lack p58IPK produced less proinsulin and insulin overall. But the most striking result came when researchers reintroduced p58IPK into cells that lacked it. The protein-folding machinery sprang back to life, proinsulin was properly trafficked out of the cell, and misfolded accumulation stopped cold. Critically, p58IPK could not work alone—none of these benefits occurred unless BiP was also present.
The team then tested whether simply producing more BiP could compensate for missing p58IPK. It could not. When BiP was overexpressed without p58IPK, cells showed only modest improvements in proinsulin folding and transport. Only when both partners were present at normal levels did the improvements become markedly significant. As Jang observed, the system functions like tennis doubles—BiP simply cannot win the match alone.
The findings open a new therapeutic avenue. By boosting the protein-folding capacity of beta cells through p58IPK and its partners, researchers may be able to prevent the cellular stress that allows diabetes to take hold. The team also identified other partner proteins involved in proinsulin folding and quality control, though their specific roles remain under investigation. Future research will determine whether enhancing this molecular partnership could slow or prevent insulin-producing cells from failing, transforming how scientists approach diabetes treatment before irreversible damage occurs.